Blood Biomarkers Predict Neuroendocrine Tumor Response to Radiopharmaceutical Therapy
A simple blood draw can help determine if peptide receptor radionuclide therapy is effective in a patient with neuroendocrine cancer.
Read MorePosted by Andy Lundin | Apr 7, 2023 | Unknown Origin & Other Cancer Types |
A simple blood draw can help determine if peptide receptor radionuclide therapy is effective in a patient with neuroendocrine cancer.
Read MorePosted by Andy Lundin | Apr 4, 2023 | Cancer |
Stilla Technologies and Atila BioSystems agreed to market digital PCR kits and assays produced by Atila for use on Stilla’s naica system.
Read MorePosted by Andy Lundin | Mar 27, 2023 | Cancer |
SEngine has been certified through the NY State Department of Health’s CLEP program to perform the PARIS Test on samples from the state.
Read MorePosted by Andy Lundin | Mar 9, 2023 | Leukemia |
Research shows benefits of screening patients in remission from acute myeloid leukemia for residual disease prior to a bone marrow transplant.
Read MorePosted by Andy Lundin | Feb 27, 2023 | Infectious Diseases |
Researchers have recommended a method to help diagnose preschool age children with primary ciliary dyskinesia (PCD).
Read More